2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2024
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
Khawaja M, Naqash A, Schneider R, Shastri A, Stahl M, Moser J, Abdel Karim N, Madanat Y, Jonas B, Stein E, Gadgeel S, McCloskey J, Gollerkeri A, Perea R, Chutake Y, Agarwal S, Henrick P, Shi K, Daver N. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). Journal Of Clinical Oncology 2024, 42: 3084-3084. DOI: 10.1200/jco.2024.42.16_suppl.3084.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaMouse double minute 2Arm BArm AAdverse eventsSolid tumorsOpen-label phase 1 studyMouse double minute 2 inhibitorUpregulated p53 activityDecreased oral intakeMerkel cell carcinomaAdenoid cystic carcinomaPhase 1 studySolid tumor typesAcute apoptotic responseDose-dependent increaseGDF-15 proteinPreclinical PDX modelsWild-type p53Anti-tumor activityDouble minute 2Upregulation of CDKN1AR/R AMLDose escalationTumor regression
2023
Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL
Luskin M, Shimony S, Keating J, Stock W, Hock H, Garcia J, Stahl M, Galinksy I, Leonard R, Weiner H, Flamand Y, Neuberg D, Stone R, Letai A, Winer E, Konopleva M, Jain N, DeAngelo D. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. Blood 2023, 142: 2875. DOI: 10.1182/blood-2023-174269.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAcute lymphoblastic leukemiaMeasurable residual diseaseMulticolor flow cytometryAllogeneic hematopoietic stem cell transplantationCentral nervous systemComplete remissionB-ALLT-ALLOlder ptsPhiladelphia chromosome (Ph)-negative acute lymphoblastic leukemiaFollow-upDiffuse large B-cell lymphomaComplication of cardiac surgeryMRD negativityLarge B-cell lymphomaRefractory acute lymphoblastic leukemiaCentral nervous system leukemiaRelapsed ALLDiagnosed ALLChemo-resistant diseaseHigh-risk geneticsMini-hyper-CVDBCL2 inhibitor venetoclaxMedian follow-upA Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults
Luskin M, Murakami M, Keating J, Winer E, Garcia J, Stahl M, Wadleigh M, Flamand Y, Neuberg D, Galinsky I, Leonard R, Hagopian E, Weizer C, McLanahan C, Stone R, Wang E, Stock W, DeAngelo D. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. Blood 2023, 142: 965. DOI: 10.1182/blood-2023-174246.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaDose-limiting toxicityMaximum tolerated doseStem cell transplantationPhase I studyCML-LBCDose escalationAllogeneic stem cell transplantationBCR-ABL1-positive acute lymphoblastic leukemiaCell line xenograft modelsPatient-derived xenograft modelsBlast phase CMLEscalating daily dosesPhase 2 doseLymphoid blast crisisBiomarkers of responseDurability of responseChronic myeloid leukemiaABL1 inhibitorsDose expansionEscalating dosesBlast crisisDeep remissionExpansion cohortTolerated dose
2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia
Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAged, 80 and overAntibodies, BispecificAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowBreast NeoplasmsCarcinoma, Transitional CellCytarabineFemaleHumansLymphoma, B-CellMercaptopurineMethotrexateNeoplasms, Second PrimaryPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSalvage TherapyUrinary Bladder NeoplasmsVincristineConceptsB-cell precursor acute lymphoblastic leukemiaAcute lymphoblastic leukemiaFrontline therapyLymphoblastic leukemiaPatientsTherapyLeukemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply